Sign in
CompletedEarly phase 1

Supportive Treatment and Antibiotics for Mild Pediatric Pneumonia

Key facts

Who runs it
Ann & Robert H Lurie Children's Hospital of Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
2 people enrolled
Started
9 Jan 2023
Ended
31 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Supportive Care + Amoxicillin
  • Supportive Care + Placebo (no antibiotics)
Record updated
15 February 2024

Who can take part

Age
12 months to 71 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Age 12-71 months; and
  • Diagnosis of CAP, defined using established criteria:; Signs and symptoms of lower respiratory tract infection (LRTI), defined as any of the following:; new or different cough; or; new or different sputum production; or; chest pain; or; dyspnea/shortness of breath; or; documented tachypnea; or; abnormal findings consistent with LRTI on physical examination (e.g., crackles/rales, rhonchi, wheezing) and; Fever, defined as tactile temperature at home or measured temperature ≥38ºC rectal, ≥37.7ºC oral, or ≥37.5ºC axillary, and; Clinician diagnosis of CAP,
  • Intention to treat as an outpatient after ED/primary care visit, and
  • Mild disease, defined as lack of respiratory distress per adapted Pediatric Infectious Diseases Society/Infectious Diseases Society of America criteria: none of the following: dyspnea, concerning retractions per treating clinician, grunting, nasal flaring, apnea, altered mental status, SpO2<93% in room air, or respiratory rate >50 breaths per minute for ages 12-24 months or respiratory rate > 40 breaths per minute if age>24 months

Who cannot take part

  • Incomplete immunization status (<2 doses of Hib and pneumococcal vaccines); or
  • Systemic antibiotic receipt (more than 1 dose) within the previous two weeks of CAP diagnosis; or
  • Diagnosed with pneumonia in the previous month; or
  • Current enrollment in another clinical trial of an investigational agent; or
  • Previous enrollment in this trial; or
  • Chronic complex medical conditions (chronic heart disease followed by cardiology, chronic lung disease (not including asthma), congenital airway or lung malformations, cystic fibrosis, tracheostomy tube, requiring positive-pressure ventilation, neuromuscular disorders affecting the lungs or chest wall); or
  • Radiographic findings of complicated pneumonia (pleural effusion larger than trace in size, empyema, [complex/septated collection] abscess, necrotic lung disease); or
  • Pneumonia known to be due to bacterial source at the time of enrollment, as documented by blood culture or PCR if available, or another clear source of bacterial infection requiring immediate antibiotics; or
  • Severe (type 1) drug allergy to amoxicillin; or
  • Any other condition that in the judgement of investigators or the clinical team could affect safety of the subject; or
  • Known allergy to milk and/or red dye
  • Conditions that compromise the immune system (HIV with CD4 count less than 400, primary immunodeficiency, asplenia, sickle cell disease, receipt of hematopoietic stem cell or solid organ transplant, cancer on active chemotherapy, immunosuppressive agents, daily corticosteroids for more than 7 consecutive days in past 14 days); or
  • Hospitalization within one-month preceding study visit; or
  • Radiographic findings of a consolidation of a concerning size or complexity in the view of the treating clinician; or
  • Provider diagnosis of aspiration pneumonia; or
  • No access to a telephone or video technology for follow-up; or
  • Parent/guardian non-English or non-Spanish speaking; or

Where in United States

  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States

About the trial

What the trial wants to find out

National guidelines make two recommendations for treatment of young children with mild pneumonia - one to avoid routine antibiotics and another to use narrow-spectrum antibiotics. No studies have compared the effectiveness of these two approaches. This pilot study will evaluate study processes and feasibility of a future clinical trial that proposes to test whether low-risk children managed as outpatients with mild community-acquired pneumonia (CAP) treated with supportive treatment without antibiotics will have a similar clinical response, with fewer adverse effects, compared with those treated with a supportive treatment plan that includes antibiotics.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Randomization to receive either oral placebo or amoxicillin for a standard course (7 days)

    Treatment: Supportive Care + Placebo (no antibiotics)

  • AmoxicillinExisting treatment, for comparison

    Randomization to receive either oral amoxicillin or placebo for a standard course (7 days)

    Treatment: Supportive Care + Amoxicillin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
15 February 2024